The effect of UCB1577571 and CA050_01953 in the transplant model of psoriasis.

Withdrawn

• Conditions: 10014982; psoriasis

• Registration Number: NL-OMON43021
• Lead Sponsor: Derphartox

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

Patients with moderate to severe psoriasis

Exclusion Criteria

Volunteers undergoing UV/light therapy or taking systemic drugs such as cyclosporin A or methotrexate
Volunteers using local topical corticosteroids
Volunteers developing psoriasis at wound sites (Köbner phenomenon)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Effect on typical psoriasis skin features after treatment with UCB1577571 en<br /><br>CA050_01953.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-</p><br>